856. Adulteration and misbranding of cascara compound tablets and Pentabisarsen ampuls. U. S. v. Max Gold and Irving Levine (Gold Leaf Pharmacal Co.). Plea of guilty. Fine, $500 on counts 2 and 4. Sentence suspended and defendants placed on probation for 1 year on counts 1 and 3.

Name: 856. Adulteration and misbranding of cascara compound tablets and Pentabisarsen ampuls. U. S. v. Max Gold and Irving Levine (Gold Leaf Pharmacal Co.). Plea of guilty. Fine, $500 on counts 2 and 4. Sentence suspended and defendants placed on probation for 1 year on counts 1 and 3.
Creator: National Library of Medicine
Published: 2026-06-21T05:56:47+08:00

Food and Nutrition Information Center2026-06-21 收录

药品监管

食品药品合规

数据链接：

https://fdanj.nlm.nih.gov/catalog/ddnj00856 数据链接链接失效反馈

官方服务：

资源简介：

Case Number: 856 Collection: Drugs and Devices, 1940-1963 Evidence Numbers: F. D. C. No. 6466. Sample Nos. 69921-E, 69925-E. Date Issued: May 1944 Seizure Dates: May 9 to 12, 1941 Product Keywords: cascara compound tablets and Pentabisarsen ampuls Defendant Names: Max Gold and Irving Levine, trading as the Gold Leaf Pharmacal Co., New Rochelle, N. Y. Court Jurisdiction: Southern District of New York Seizure Location: Connecticut Shipped From: New York Shipped To: Connecticut Copyright: The National Library of Medicine believes this item to be in the public domain (More information)

提供机构：

National Library of Medicine

856. Adulteration and misbranding of cascara compound tablets and Pentabisarsen ampuls. U. S. v. Max Gold and Irving Levine (Gold Leaf Pharmacal Co.). Plea of guilty. Fine, $500 on counts 2 and 4. Sentence suspended and defendants placed on probation for 1 year on counts 1 and 3.

资源简介：

相关数据集